Neurocrine says valbenazine improves tardive dyskinesia impacts in KINECT-PRO analysis
NBIX•Neurocrine Biosciences said KINECT-PRO analyses found valbenazine improved the socio-emotional and physical impacts of tardive dyskinesia. The company will present research on Nov. 7, 2026, at the NEI Fall Congress; separate analyses address symptomatic remission and drug exposure.
1. Research presentations planned
Neurocrine Biosciences will present tardive dyskinesia research on Nov. 7, 2026, at the NEI Fall Congress in Colorado Springs. KINECT-PRO analyses found valbenazine improved the condition’s socio-emotional and physical impacts, while separate analyses examine symptomatic remission across two clinical trials. A PET study in healthy male adults found once-daily valbenazine provided greater, more predictable exposure than extended-release deutetrabenazine.
